PHARMA · R&D
Discovery Synthesis · The Core Story
Helixor Therapeutics · Global · Replace $18Bn patent cliff · $8.4Bn R&D flat
Delta
465 bps
155 bps
spread — same data, same $8.4Bn R&D budget
0 of 5 teams started R1 with a patent-cliff lens
firm-level signal
Helixor Therapeutics has $40Bn in net sales, $8.4Bn in R&D spend, and an $18Bn patent cliff arriving within five years. The mandate is to build a pipeline that replaces what is expiring. Five cross-functional teams ran the same simulation. Delta scored 465 bps. Alpha and Epsilon scored 310–320 bps. The 155 bps spread came from the same dataset, the same $8.4Bn budget, and the same patent cliff. Every team hit the same three traps: late-stage focus in R1, scar-tissue governance in R2, and compounding delays in R3.
01
Put the cliff on the first slide
Start every portfolio session with: how much of the $18Bn cliff does our pipeline cover? Not: which project is closest to approval? The opening frame determines the allocation logic. Change the frame — 155 bps of spread narrows.
02
Name the kill incentive conflict now
Leaders are rewarded for keeping projects alive, not for stopping them quickly. No team named this before R3. An 18-month Phase II delay costs 15–20% of NPV. Build one kill forum with override authority. Owner: Head of R&D Operations. Deadline: 60 days.
03
Cut internal decision latency in half
12-month internal decision cycles cost 5–10% NPV per round. Target: 6 months. Write the target on the R&D dashboard today. A single-owner accountability model per asset is the mechanism — not another committee.
PHARMA · R&D
Overall Combined · All 5 Teams
155 bps spread — same data, same $8.4Bn R&D budget
Delta
465 bps
310–320 bps
Alpha & Epsilon range
155 bps
spread — same data, same $8.4Bn R&D budget
0 of 5
0 of 5 teams started R1 with a patent-cliff lens
TeamIdentityScoreMix OpenedKey Pattern
AlphaScience-First310 bpsNoScar tissue → safety governance; mix never opened
BetaLate-Stage First340 bpsNoSave-the-launch bias; post-2030 gap widened
GammaCommercial-Pull355 bpsPartialMe-too protection; innovative assets killed early
DeltaGovernance-First465 bpsYesSlow early — recovered through kill discipline
EpsilonOne R&D320 bpsNoRight language, too many committees; limited kill
Delta performed best. Alpha and Epsilon scored at the bottom. The 155 bps spread came from the same dataset, same mandate, and same constraints. Every team hit the same three traps in the same order.
The simulation selects for a dominant behaviour pattern regardless of team composition. Delta's advantage was not superior skill — it was an identity least attached to the default first instinct. The system design produced the spread.
The offsite design is the intervention. Change the opening frame for the next session. The spread narrows when the first question changes — not when team composition changes.
PHARMA · R&D
Team Arc · Alpha
Score: 310 bps · Target: 500 bps · +40 bps mix opportunity in data — never opened across all rounds
310 bps
Alpha final score (target: 500 bps)
+40 bps mix opportunity in data
+40 bps mix opportunity in data — never opened across all rounds
3 of 8 dossiers opened in R1
3 of 8 dossiers opened in R1 — all cost-side
R1–R4
Same trap pattern every round — process unchanged
R1
Late-stage focus
3/8 dossiers
all cost-side
R2
Scar-tissue gov.
52/100
0/3 growth picks
R3
Compounding delays
3 launches
40–50% cliff
R4
Board case
310 bps
vs 500 target
Alpha opened with individual asset analysis (Science-First identity), chose safety governance in R2, failed to surface and hold the supply expiry risk from R1, and delivered 310 bps against a 500 bps Board target. The +40 bps mix opportunity was in the data in R1 and was never opened across all four rounds.
Alpha's arc reveals a team with deep scientific conviction but no shared portfolio language. The scar tissue from past failures produced protective confidence signalling and safety-only governance, which then compounded into delivery shortfall. The science was strong; the decision system failed it.
One fix before the next Board cycle: introduce the portfolio cliff-coverage metric as Alpha's primary opening frame — not individual asset quality. If the cliff gap is not the first number on the table, the team will default to science discussion.
PHARMA · R&D
Round 1 · System
How does the process perform under real time pressure and information constraints?
$18Bn
Patent cliff revenue at risk within 5 years
$13Bn
Risk-adjusted NPV of Phase II–III pipeline
3 of 8
R1 dossiers opened — all cost-side
0 of 5
Teams opened with a patent-cliff lens
All five teams spent Round 1 analysing individual late-stage projects. No team opened with a portfolio-vs-cliff view. Phase III assets with NPV 0.8–1.3× cost were retained without challenge. Team Alpha opened 3 of 8 dossiers — all on cost, none on the mix or cliff-coverage gap.
When the first instinct is late-stage rescue, the pipeline looks busy but the cliff gap stays hidden. Risk-adjusted Phase II–III value of $13Bn covers only ~72% of the $18Bn cliff. The system is rewarding activity, not value creation.
Start every R&D portfolio review with one picture: risk-adjusted pipeline NPV plotted against cliff exposure. If the gap is not named in the first 15 minutes, the session is managing the past. Owner: Head of Portfolio Strategy.
TEAM POLL
In your last R&D or portfolio review, what opened the session?
Arena's view: In the simulation, 0 of 5 teams opened with cliff coverage — despite the $5Bn coverage gap being calculable from data available in Round 1. Individual programme framing is the default. It makes the pipeline look active and the cliff gap invisible.
PHARMA · R&D
Round 2 · People
How do leaders actually decide under governance and conviction pressure?
28%
R&D spend on late-stage rescue and overruns
52/100
Alpha confidence score R2 (stated: high)
2 of 2
Concerns dropped in session — neither recorded
0 of 3
Governance picks that improve performance
In Round 2, Team Alpha's stated confidence was high at 52/100 but they chose risk-mitigation governance in all three picks — none improved portfolio performance. Two material concerns were raised and dropped in session; neither was recorded. 28% of the R&D budget is absorbed by late-stage rescue and overruns.
High stated confidence and risk-averse decisions are the classic scar-tissue pattern. Teams that have been through multiple failed transformations protect themselves by signalling certainty while choosing safety. The governance system rewards this: 14–18 committees, slow decision cycles, no shared metric of success.
Name the incentive conflict before the next governance review: field leaders are rewarded for keeping projects alive, not for killing them quickly. Build one kill forum with authority to override local incentives. Owner: Head of R&D Operations. Deadline: 60 days.
INFERENCE CHECK
28% of Helixor's R&D budget is absorbed by late-stage rescue and overruns. No team addressed this as a structural problem in R2. What explains this most accurately?
PHARMA · R&D
Round 3 · System × People
What happens when shocks and pressure interact with the system and people inside it?
3 launches
Status quo — 40–50% cliff replaced
7–8 yrs
Phase II → launch cycle time (peers: 5–6)
$14Bn
Cost per launch (peers: $6–8Bn)
0 of 5
Teams named the incentive conflict before R3
Over four to five simulated years, the status quo produced 3 launches and replaced 40–50% of cliff revenue. Cycle time averaged 7–8 years versus peer benchmark of 5–6. Cost per launch reached $14Bn versus $6–8Bn for top-quartile peers. A supply expiry risk raised in R1 minute 9 was never recorded and materialised as a R3 shock.
The system compounds its own friction. Decision latency (12 months internal), rescue bias, and governance layers each take a percentage off NPV. By year 5, those percentages add up to half the cliff gap. The unrecorded R1 concern is the clearest signal: the system cannot surface and hold risk.
Reduce internal decision latency from 12 months to 6 months on key Phase II go/no-go decisions. Each 6-month delay costs 5–10% of asset NPV. Write the target in the R&D dashboard now. Owner: CMO. Mechanism: single-owner accountability per asset.
DECISION STAMP
In your R&D governance model, when a concern is raised verbally in a portfolio or milestone review — what most commonly happens to it?
🔒 Stamped. Your response has been recorded.
Arena's view: In the simulation, 2 of 2 concerns raised in Round 1 were dropped and not recorded. The supply expiry risk that materialised in Round 3 was first surfaced in Round 1 minute 9. The gap between a concern raised and a concern held is a governance gap, not a capability gap.